Iturra‑Mena, Ann M.
Kangas, Brian D. http://orcid.org/0000-0002-4597-9801
Luc, Oanh T.
Potter, David
Pizzagalli, Diego A. http://orcid.org/0000-0002-7772-1143
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (P50 MH119467-02)
Article History
Received: 2 October 2022
Revised: 18 December 2022
Accepted: 31 December 2022
First Online: 16 January 2023
Competing interests
: Over the past 3 years, DAP has received consulting fees from Albright Stonebridge Group, Boehringer Ingelheim, Compass Pathways, Engrail Therapeutics, Neumora Therapeutics (formerly BlackThorn Therapeutics), Neurocrine Biosciences, Neuroscience Software, Otsuka, Sunovion, and Takeda; he has received honoraria from the Psychonomic Society and American Psychological Association (for editorial work) and from Alkermes; he has received research funding from the Brain and Behavior Research Foundation, Dana Foundation, Wellcome Leap, Millennium Pharmaceuticals, and NIMH; he has received stock options from Compass Pathways, Engrail Therapeutics, Neumora Therapeutics, and Neuroscience Software; he has a financial interest in Neumora Therapeutics, which has licensed the copyright to the human version of the probabilistic reward task through Harvard University. No funding from these entities was used to support the current work, and all views expressed are solely those of the authors. All other authors have no conflicts of interest or relevant disclosures.